cytarabine; daunorubicin - Profile

What are the generic sources for cytarabine; daunorubicin and what is the scope of freedom to operate?

Cytarabine; daunorubicin is the generic ingredient in one branded drug marketed by Jazz Pharms Therap and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cytarabine; daunorubicin has one hundred and forty-seven patent family members in twenty-six countries.

Summary for cytarabine; daunorubicin

International Patents:	147
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cytarabine; daunorubicin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for cytarabine; daunorubicin

Constraining patent/regulatory exclusivity:

TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for cytarabine; daunorubicin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	8,518,437		Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	10,028,912*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	7,850,990*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	8,022,279*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	8,092,828*PED				Y
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes	9,271,931*PED				Y

Expired US Patents for cytarabine; daunorubicin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Jazz Pharms Therap	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017	8,431,806

EU/EMA Drug Approvals for cytarabine; daunorubicin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Jazz Pharmaceuticals Ireland Limited	Vyxeos liposomal (previously known as Vyxeos)	daunorubicin, cytarabine	EMEA/H/C/004282Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).	Authorised	no	no	yes	2018-08-23

International Patents for cytarabine; daunorubicin

Country	Patent Number	Title	Estimated Expiration
Portugal	2768484
South Korea	20200057104
Germany	60222580
Cyprus	1119631
Spain	2347534
Japan	2011157376	LIPOSOME LOADING WITH METAL ION

Supplementary Protection Certificates for cytarabine; daunorubicin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3300601	27/2022	Austria		PRODUCT NAME: KOMBINATION VON DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: EU/1/18/1308 (MITTEILUNG) 20180827
2768484	2019041	Norway		PRODUCT NAME: KOMBINASJON AV DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180831
1744764	C01744764/01	Switzerland		PRODUCT NAME: DAUNORUBICIN UND CYTARABIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68014 17.02.2022
1744764	18C1047	France		PRODUCT NAME: DAUNORUBICINE + CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2768484	384 1-2020	Slovakia		PRODUCT NAME: KOMBINACIA DAUNORUBICINU A CYTARABINU; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2768484	132019000000144	Italy		PRODUCT NAME: DAUNORUBICINA E CITARABINA(VYXEOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1308, 20180827

Investment Scenario and Fundamentals Analysis of Cytarabine and Daunorubicin

Last updated: February 22, 2026

This report evaluates the investment potential of the combination of cytarabine and daunorubicin, focusing on market dynamics, clinical development, regulatory status, economic fundamentals, and competitive landscape.

What Are Cytarabine and Daunorubicin?

Cytarabine (also known as Ara-C) is a chemotherapy agent primarily used for treating acute myeloid leukemia (AML). It is a nucleoside analog that inhibits DNA synthesis, leading to cell death.

Daunorubicin (also known as daunorubicin hydrochloride) is an anthracycline antibiotic that intercalates into DNA, causing DNA strand breaks. It is used in AML, acute lymphoblastic leukemia (ALL), and some lymphomas.

Both drugs have established roles in chemotherapy regimens; their combination remains standard for AML induction therapy.

Market Overview and Revenue Potential

Aspect	Details
Global AML market size (2022)	USD 1.07 billion, projected to reach USD 1.69 billion by 2030, CAGR 5.8% (Fortune Business Insights)[1].
Current treatment landscape	Standard chemotherapy regimens prioritize cytarabine and daunorubicin; no generic substitutes currently dominate first-line AML therapy in developed markets.
Market segmentation	Hospital-based intravenous administration accounts for 85% of sales; outpatient use is limited.

Key Drivers:

• Increasing AML incidence among aging populations.
• Adoption of combination regimens despite high costs.
• Regulatory approvals for novel formulations or combination therapies.

Challenges:

• The emergence of targeted therapies and immunotherapies (e.g., Venetoclax) as alternatives.
• Biosimilar competition for anthracyclines in some markets.
• Treatment costs and side effects limiting broader adoption.

Clinical Development & Regulatory Status

Cytarabine and daunorubicin have been on the market since the 1970s, with extensive data supporting their efficacy and safety for AML.

Patents and Exclusivity

Drug	Original Patent Expiration	Patent Status (2023)	Regulatory Status
Cytarabine	1990s	Expired	Generic versions available; FDA-approved in multiple formulations[2].
Daunorubicin	1970s	Expired	Several biosimilars and generics approved.

There are limited opportunities for new patents; however, reformulations, delivery systems, or biomarkers can layer IP protection.

Clinical Trials Activity

• Few ongoing clinical trials examining combinations for novel indications.
• Investigations into liposomal formulations to enhance delivery and reduce toxicity are ongoing.

Economic Fundamentals and Investment Risks

Cost and Pricing

Aspect	Details
Average wholesale price per treatment course	USD 20,000–30,000 for AML regimens[3].
Manufacturing costs	Low, given the age of formulations; biosimilar entry can further decrease prices.

Patent and Market Entry Barriers

• High barriers due to established standard of care, patent expirations, and manufacturing assets.
• Generic manufacturing reduces margins but enhances accessibility and volume.

Competitive Landscape

• Multiple generic producers exist worldwide.
• Limited innovation for these compounds; focus shifts to new formulations.

Regulatory & Reimbursement Environment

• Favorable for generics and biosimilars.
• Reimbursement policies vary; some countries favor cost-effective treatments.

Investment Opportunities and Considerations

Potential Areas

1. Biosimilar Competition: High-volume, low-margin market; investment in production capacity could be profitable.
2. Reformulation: Liposomal or targeted delivery formulations could command premium pricing if supported by clinical advantages.
3. Combination Strategies: Development of adjuncts or companion diagnostics may extend product lifecycle.

Risks

• Market saturation due to generics.
• Competition from new agents, such as FLT3 inhibitors or BCL-2 inhibitors.
• Shifts toward precision medicine, reducing reliance on traditional chemotherapies.

Key Takeaways

• The core drugs have declining patent protections but maintain a steady revenue base due to entrenched clinical use.
• Market growth is driven by AML incidence and healthcare system adoption, but faces competition from targeted drugs.
• Investment prospects are stronger in reformulations, biosimilars, or value-added formulations than in the original compounds.
• Going forward, drug developer focus should consider clinical innovation, regulatory pathways, and market dynamics.

FAQs

1. Is there scope for patenting new formulations of cytarabine or daunorubicin?

Yes. Liposomal delivery systems, targeted conjugates, or combination delivery mechanisms can be patented if they demonstrate clinical benefits.

2. What is the competitive advantage of biosimilars for daunorubicin?

Lower manufacturing costs and price competition reduce healthcare expenditure, provided biosimilar quality and bioequivalence are demonstrated.

3. How does the emergence of targeted therapies affect the market for traditional chemotherapy agents?

Targeted agents challenge the position of traditional chemotherapies by offering more effective, less toxic options but are often more expensive and less established in current treatment protocols.

4. Are there upcoming regulatory changes that influence AML drug development?

Regulatory agencies are increasingly supportive of biosimilars and reformulations. In some regions, accelerated approval pathways are available for innovative delivery systems.

5. What are the main clinical limitations of cytarabine and daunorubicin?

High toxicity profiles, resistance development, and the need for hospitalization limit their utility and promote the development of alternative therapies.

References

[1] Fortune Business Insights. (2022). Acute Myeloid Leukemia Market Size, Share & Industry Analysis.

[2] Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.

[3] IQVIA. (2021). Pharmaceutical Pricing Data.

---

This document provides a comprehensive review of investment fundamentals for cytarabine and daunorubicin, incorporating market, clinical, regulatory, and competitive insights.